Halozyme initiated with an Overweight at Wells Fargo

Wells Fargo analyst Mohit Bansal initiated coverage of Halozyme Therapeutics with an Overweight rating and $65 price target. The analyst lists seven reasons to own Halozyme, saying it is a "profitable, high-growth company with earnings power "to grow at 21% annually through the end of the decade. Investors are overly focused on 2027 intellectual property concerns but a patent analysis suggests multiple products and pipelines having protection into mid-2030s, Bansal tells investors in a research note. Halozyme’s five core products explain much of current value at $51 per share, "while multiple others in development represent free call options," Bansal tells investors in a research note.